Child-Parent Screening for Hypercholesterolemia Feasible

Share this content:
Child-Parent Screening for Hypercholesterolemia Feasible
Child-Parent Screening for Hypercholesterolemia Feasible

THURSDAY, Oct. 27, 2016 (HealthDay News) -- Screening for hypercholesterolemia is feasible at routine child immunization visits in primary care practices, according to a study published in the Oct. 27 issue of the New England Journal of Medicine.

David S. Wald, M.B.B.S., from the Wolfson Institute of Preventive Medicine at Queen Mary University of London, and colleagues obtained capillary blood samples to measure cholesterol levels and test for familial hypercholesterolemia mutations in 10,095 children aged 1 to 2 years. The authors examined the efficacy and feasibility of screening in primary care practice.

The researchers found that 28 children (0.3 percent) were identified who had positive screening results for familial hypercholesterolemia using a prespecified cholesterol cut-off value of 1.53 multiples of the median (MoM), including 20 with a familial hypercholesterolemia mutation and eight with a repeat cholesterol level of at least 1.53 MoM. Overall, 17 children had a cholesterol level of less than 1.53 MoM and had a familial hypercholesterolemia mutation. The overall prevalence of mutation was one in 273 children. Use of an initial cholesterol cut-off value of 1.35 MoM plus a mutation or two cholesterol values of 1.50 MoM or more identified 40 children with positive screening results for familial hypercholesterolemia (0.4 percent) and 40 parents with positive screening results for familial hypercholesterolemia.

"Child-parent screening was feasible in primary care practices at routine child immunization visits," the authors write.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »